12 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Exploring the Existing Drug Space for Novel pTyr Mimetic and SHP2 Inhibitors.
Indiana University School of Medicine
A potent and selective inhibitor for the UBLCP1 proteasome phosphatase.
Indiana University
Therapeutic potential of targeting the oncogenic SHP2 phosphatase.
Indiana University School of Medicine
A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases.
Indiana University School of Medicine
Discovery and evaluation of novel inhibitors of mycobacterium protein tyrosine phosphatase B from the 6-Hydroxy-benzofuran-5-carboxylic acid scaffold.
Indiana University School of Medicine
Small molecule receptor protein tyrosine phosphatase¿ (RPTP¿) ligands that inhibit phosphatase activity via perturbation of the tryptophan-proline-aspartate (WPD) loop.
Bristol-Myers Squibb Research and Development
Structure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase Inhibitors.
Eli Lilly
Design and synthesis of potent, non-peptidic inhibitors of HPTPbeta.
Procter & Gamble Pharmaceuticals
Inhibition of Low Molecular Weight Protein Tyrosine Phosphatase by an Induced-Fit Mechanism.
Purdue University